659 NHL Clinical Trials Recruiting Now (October 2026): Non-Hodgkin Lymphoma — CD20 Bispecifics, CAR-T, BTK, DLBCL/FL/MCL

Last updated: October 28, 2026

Answer a few questions to find clinical trials matched to your specific Non-Hodgkin Lymphoma situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Current Clinical Trial Landscape

Active research areas in 2026:

CD20×CD3 bispecific antibodies moving to first-line: epcoritamab, glofitamab, mosunetuzumab, odronextamab
CAR-T cell therapy: axi-cel, liso-cel, tisa-cel — now testing earlier lines and combinations
ADCs: zilovertamab vedotin (ROR1), polatuzumab vedotin combinations
Next-gen BTK inhibitors and degraders: pirtobrutinib, NX-5948
Bispecific + lenalidomide combinations for indolent NHL

Standard of care: DLBCL: R-CHOP (first-line), CAR-T or bispecific (relapsed); brentuximab vedotin + lenalidomide + rituximab after ≥2 lines for patients ineligible for transplant or CAR-T (FDA Feb 2025). Follicular: rituximab-based combos, then lenalidomide + rituximab with epcoritamab (Nov 2025) or tafasitamab (Jun 2025), bispecifics, or liso-cel CAR-T. Marginal zone: liso-cel CAR-T after ≥2 lines (Dec 2025). Mantle cell: BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib); after a BTK inhibitor and ≥2 lines, the BCL-2 inhibitor sonrotoclax (Beqalzi) (FDA accelerated approval May 13, 2026; ORR 52%, median duration of response 15.8 months), alongside pirtobrutinib and CAR-T (brexu-cel; liso-cel after a BTK inhibitor, May 2024). T-cell NHL: CHOP-based, then options limited.

Recruiting Trials by NHL Subtype

Diffuse Large B-Cell Lymphoma (DLBCL)

The most common aggressive NHL — bispecifics and CAR-T are transforming relapsed disease:

First-line:
- NCT05820841 - Acalabrutinib + R-miniCHOP in older adults with untreated DLBCL (Phase 3, activated 2026-06-30 — BTKi + reduced-intensity R-CHP for the frail-elderly under-studied DLBCL population)
- NCT06091865 - Odronextamab + chemo vs rituximab + chemo in DLBCL (Phase 3, activated 2026-06-17 — head-to-head Regeneron CD20xCD3 bispecific chemo-combination challenge to R-CHOP standard)
Relapsed/refractory — bispecifics:
- NCT06084936 - Glofitamab monotherapy vs investigator's choice in R/R DLBCL (Phase 3)
- NCT07215585 - AZD0486 1L therapy for elderly or unfit patients with LBCL (Phase 3, CD19xCD3 bispecific 1L entrant)
ADCs:
- NCT05139017 - Zilovertamab vedotin (ROR1 ADC) + R-CHP in untreated DLBCL (Phase 3)
- NCT06717347 - Zilovertamab vedotin + R-CHP in DLBCL (Phase 3)
CAR-T:
- NCT07502118 - NexCAR19 (talikabtagene autoleucel) in R/R B-cell malignancies (Phase 3)
- NCT07479797 - KITE-753 vs Axicabtagene Ciloleucel in R/R LBCL (Phase 3, the first head-to-head Phase 3 between next-gen CD19 CAR-T candidates and the FDA-approved standard — active, not recruiting as of October 2026)
- NCT07188558 - Ronde-cel vs investigator's choice CD19 CAR T-cell therapy in large B-cell lymphoma (Phase 3, activated 2026-06-09 — second head-to-head Phase 3 between a next-gen CD19 CAR-T candidate and the FDA-approved standard, joining KITE-753 in the R/R LBCL CAR-T comparator race)

Follicular Lymphoma + Marginal Zone Lymphoma

Indolent but incurable — bispecifics and BTK inhibitors offer new options:

- NCT06549595 - Surovatamig + rituximab in previously untreated FL (Phase 3)
- NCT06149286 - Odronextamab + lenalidomide in R/R FL (Phase 3)
- NCT06091254 - Odronextamab vs rituximab + chemo/lenalidomide in FL / MZL (Phase 3, activated 2026-06-26 — Regeneron CD20xCD3 bispecific head-to-head monotherapy challenge to rituximab-containing chemo backbones)
- NCT06337318 - Rituximab vs Mosunetuzumab head-to-head in low tumor-burden FL (Phase 3, the first FL Phase 3 testing if a CD20×CD3 bispecific can replace rituximab monotherapy in low-burden setting)

Mantle Cell Lymphoma

BTK inhibitor resistance is the key challenge — next-gen agents and bispecifics:

- NCT05976763 - Continuous vs intermittent zanubrutinib for MCL (Phase 3)
- NCT07409428 - HMPL-760 + R-GemOx vs placebo + R-GemOx in R/R MCL (Phase 3)
- NCT07377578 - Rocbrutinib (novel BTK inhibitor) vs investigator's choice of BTK inhibitor in MCL (Phase 3)

Peripheral T-Cell Lymphoma (PTCL)

Rare and aggressive — few approved options beyond CHOP:

- NCT06561048 - Soquelitinib vs standard in R/R peripheral T-cell lymphoma (Phase 3)
- NCT06522737 - Duvelisib vs gemcitabine or bendamustine in R/R PTCL (Phase 3)
- NCT07300514 - Golidocitinib maintenance for PTCL (Phase 3)

Cross-Subtype (BTK Inhibitors)

- NCT05254743 - Pirtobrutinib vs ibrutinib in CLL (Phase 3)

Showing selected notable trials. View all 659 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find non-Hodgkin lymphoma clinical trials I'm eligible for?

Enter your NHL details into ClinTrialFinder — including subtype (DLBCL, follicular, mantle cell, marginal zone, T-cell), number of prior therapies, and prior CAR-T or bispecific exposure. The AI matches you with trials in minutes.

What non-Hodgkin lymphoma trials are currently recruiting?

There are 659 recruiting interventional trials for NHL in October 2026 including 51 Phase 3 studies. New Phase 3 entrants in July 2026: AZD0486 CD19xCD3 1L LBCL (NCT07215585), KITE-753 vs Axicabtagene Ciloleucel head-to-head (NCT07479797), rituximab vs mosunetuzumab in low tumor-burden FL (NCT06337318). Active classes: CD20×CD3 bispecific antibodies (epcoritamab, glofitamab, mosunetuzumab, odronextamab), CAR-T cell therapy (axi-cel, liso-cel, tisa-cel, KITE-753, NexCAR19), BTK inhibitors and BTK degraders (pirtobrutinib, BGB-16673), ADCs (zilovertamab vedotin ROR1, polatuzumab vedotin), and novel combinations across DLBCL, FL, MCL, PTCL, CTCL.

Find NHL Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials